Many times, we become frustrated with our patients because they just don’t take diabetes seriously. One of the ways that we see this is the lack of refill persistence and medication adherence among these patients. Even with medications that you only have to take once per week, there is a …

Man, 63 years of age, type 2 diabetes, obesity, hypertension and hyperlipidemia, referred to me, a CDE, to start him on and teach him how to use insulin. He has had diabetes education in the past, tried lower carb eating and physical activity, but glucose levels still elevated. He told me he felt like a failure. He said he learned he was insulin resistant, made too much insulin, which was causing his co-morbidities. He was very resistant to start insulin, especially since he thought insulin was the cause of his problem.

Dr. Altamash Shaikh talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 3 of this Exclusive Interview, Dr. Shaikh explains the life experience among the Indians that lends itself to the development and perpetuation of diabetes.

In this week's Homerun Slides, the rate of heart failure hospitalization and all-cause mortality of patients on the placebo vs empagliflozin study.

Insulin receptor substrate molecules -- receptor substrate/docking protein: Following insulin binding and receptor autophosphorylation, the next committed step in signal transduction is tyrosine phosphorylation of intracellular proteins. To accomplish this, autophosphorylation of the beta subunit mediates noncovalent but stable interactions between the receptor and intracellular substrate proteins, and this positions these molecules for tyrosine phosphorylation by the activated insulin receptor kinase.